Ceramide has recently been regarded as a potential mediator of apoptosis. In the present study, the eects of Bcl-2 and Bax on the ceramide-mediated apoptotic pathways were examined in glioma cells overexpressing Bcl-2 or Bax. Etoposide, cisplatin and tumor necrosis factor-a induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3. The growth of C6 cells stably overexpressing either Bcl-2 or Bax was almost equal to that of the vector-transfected cells. Bax overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation. However, Bax had no eect on ceramide formation. Similar ®ndings were obtained in C6 cells and U87-MG human glioblastoma cells which were transiently overexpressed with Bax. In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. In addition, transient overexpression of Bcl-xL also exerted inhibitory eects on ceramide formation and apoptotic cell death induced by etoposide. These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release.
Introduction
The lipid mediator ceramide is emerging as a regulator involved in apoptosis as well as dierentiation Kolesnick and Hannun, 1999) , but the role of ceramide in apoptosis is still controversial. A number of extracellular stimuli, not only various cytokines including tumor necrosis factor (TNF)-a, interferon-g (Kim et al., 1991; Dressler et al., 1992) , interleukin-1b (Ballou et al., 1992) , nerve growth factor (Dobrowsky et al., 1994) , and activators of Fas receptor (Cifone et al., 1994) , but also physical stresses including heat shock, irradiation and chemotherapeutic drugs (Verheij et al., 1996; Santana et al., 1996; Jarezou et al., 1996) are shown to cause sphingomyelin (SM) hydrolysis via sphingomyelinase (SMase), leading to elevation of intracellular ceramide, although several recent reports have questioned the role of ceramide in apoptosis induced by Fas or TNF-a (Sillence and Allen, 1997; Hsu et al., 1998; Watts et al., , 1999a . The addition of exogenous ceramide has been associated with several antiproliferative responses including cell dierentiation, apoptosis, and cell cycle arrest (Okazaki et al., 1990; Kolesnick and Hannun, 1999) . These ®ndings led us to assume that ceramide may act as a common mediator of apoptotic mechanism(s). However, the mechanisms by which ceramide induces apoptosis remain poorly understood.
Among various regulators of apoptosis, the protooncogene bcl-2 is believed to play an anti-apoptotic role (Reed, 1997; Tsujimoto, 1998; Adams and Corry, 1998) . The product of the bcl-2 gene is known to play a role in promoting cell survival and preventing apoptosis induced by physical stresses including irradiation (Strasser et al., 1994) , chemotherapeutic agents (Yin and Schimke, 1996; Zhang et al., 1996) , and growth factor depletion . In contrast, the related protein Bax is shown to accelerate apoptosis and to counteract the anti-apoptotic action of Bcl-2 Yin et al., 1994) . These ®ndings suggest that the bcl-2 family and ceramide participate in either the common pathway of cell death or the redundant mechanisms activated by similar agents causing cell death. Several recent studies have shown that the inhibition of ceramide accumulation by Bcl-2 overexpression during apoptosis induced by chemotherapeutic agents, irradiation, or hypoxia (Yoshimura et al., 1998; Tepper et al., 1999) . In contrast, other studies have demonstrated that overexpression of Bcl-2 or Bcl-xL failed to prevent ceramide formation in response to certain anti-cancer drugs Allouche et al., 1997) or receptor agonists (Dbaibo et al., 1997; Wiesner et al., 1997) . At present, therefore, the mechanism underlying the Bcl-2-mediated protection against the ceramide signaling pathway is still controversial. In addition, as far as we know, there is no report regarding the eect of Bax on the ceramide signaling pathway. Therefore, these uncertain issues have tempted us to examine the interaction between Bcl-2 or Bax and the SM-ceramide signaling pathway in apoptosis.
In the present study, we investigated how the Bcl-2 family relates to the ceramide-mediated apoptotic pathway induced by etoposide (VP-16), cisplatin (CDDP), or TNF-a using C6 rat glioma cells and U87-MG human glioblastoma cells transfected with bax or bcl-2 gene. Our data suggest that Bcl-2 blocks both neutral SMase activation and release of mitochondrial cytochrome c to cytosol, and that Bax facilitates apoptosis without counteracting the function of Bcl-2 with respect to the ceramide formation.
Results
Overexpression of Bcl-2 and Bax in C6 glioma cell line C6 glioma cells were stably transfected with a neomycin resistant expression vector containing the human bcl-2 gene, followed by G418 selection and subsequent cloning. Eighteen independent clones were obtained from C6 cells transfected with the bcl-2 gene. We have chosen the clone expressing the highest level of Bcl-2 protein and designed it as C6/Bcl-2. C6 cells transfected with the murine bax gene (designated as C6/Bax) were kindly provided by Dr Keith M Rich (Vogelbaum et al., 1998) . C6 cells transfected with the empty vector were used as controls (C6/Neo). As shown in Figure 1 , C6/Bcl-2 cells displayed an intense band in the expected size of 29 kDa. However, the levels of Bax, Bcl-xL and Bad in C6/Bcl-2 cells were nearly equivalent to those of C6/Neo cells. A high expression of 21 kDa Bax protein was observed in C6/ Bax cells. It is to be noted that C6/Bax cells expressed slightly higher levels of Bcl-2 and Bcl-xL compared to those in C6/Neo cells. The levels of Bad protein were almost equivalent in the cells examined. Total number of viable cells and the percentage of dead cells as assessed by trypan blue exclusion were similar for all clones over a 5-day incubation period, suggesting that stable expression of Bcl-2 or Bax did not signi®cantly aect the growth rate and spontaneous cell death of C6 transfectants (data not shown).
Effects of Bax or Bcl-2 overexpression on apoptosis induced by etoposide C6/Neo, C6/Bcl-2, and C6/Bax cells were treated with 40 mM etoposide, and the cells with fragmented and condensed nuclei were recognized by staining with Hoechst 33258. As shown in Figure 2a , C6/Bax cells were more sensitive to etoposide in inducing apoptosis than C6/Neo cells. In contrast, the population of apoptotic cells signi®cantly decreased in C6/Bcl-2 cells compared to C6/Neo cells. However, it should be noted that apoptotic cells increased with time, indicating that Bcl-2 overexpression delayed, but not prevent, etoposide-induced apoptosis. Internucleosomal DNA fragmentation was clearly visualized by conventional agarose gel electrophoresis in C6/Neo cells at 24 and 48 h after exposure to etoposide (Figure 2b, upper) , whereas it occurred even at 12 h in C6/Bax cells (Figure 2b , middle). In C6/Bcl-2 cells, however, the DNA fragmentation was undetectable within 24 h after the etoposide treatment (Figure 2b , lower), and became evident at 48 h. In order to examine the involvement of caspases in etoposide-induced apoptosis, the eects of z-VAD.FMK, a broad spectrum caspase inhibitor, were examined. Figure 2a demonstrates a marked prevention of apoptosis by z-VAD.FMK in three types of cells.
Effects of Bcl-2 overexpression on ceramide formation by SMase activation
Signi®cant elevation of the intracellular ceramide content was seen as early as 1 h after the etoposide treatment and followed by a progressive increase up to 24 h in C6/Neo cells (Figure 3a) . A similar pro®le of ceramide formation was also observed in 14 C-serinelabeled C6/Neo cells (Figure 3b ). In addition, the [ 14 C]SM level was reciprocally decreased and the lowest level was approximately 40% of the control level at 12 h (Figure 3c ). These ®ndings suggest that the ceramide elevation would be due to SM hydrolysis by neutral SMase. Accordingly, we measured the neutral SMase activity at intervals after the etoposide treatment (Figure 3d ). In C6/Neo cells, activation of neutral SMase appeared as early as 1 h after the etoposide treatment and its activity gradually increased for up to 24 h. In contrast, the activity of acid SMase remained unchanged during the time course examined (data not shown).
Etoposide-induced increases in ceramide formation and SMase activation were apparently reduced in C6/ Bcl-2 cells (Figure 3a,d) . Similarly, in 14 C-serine-labeled Figure 1 Characterization of Bcl-2 family members in C6 transfectants. C6 cells were stably transfected with human bcl-2 gene by lipofection followed by selection of G418-resistant clones as described in Materials and methods, and the clone expressing the highest level of Bcl-2 was designed as C6/Bcl-2. C6 cells transfected with the murine bax gene (C6/Bax) were provided by Dr Keith M Rich. Bcl-2, Bax, Bcl-xL and Bad levels were compared with those in cells transfected with empty vector (C6/ Neo) by immunoblot analysis. Actin was used as loading control. Figure  3b ,c). However, both ceramide formation and SMase activation eventually increased with time, indicating that Bcl-2 overexpression delayed, but not prevented, etoposide-induced ceramide formation. These results indicate that Bcl-2 would interfere with ceramide accumulation through inhibition of neutral SMase activation.
Next, in order to rule out the intriguing note that the inhibitory eect on ceramide formation by Bcl-2 is dependent on the type of apoptotic stimuli used, we examined the SM-ceramide pathway in apoptosis induced by other stimuli, cisplatin (CDDP) as a chemotherapeutic agent and TNF-a as a receptor agonist. Exposure of either TNF-a or cisplatin caused a time-dependent apoptotic cell death of C6/Neo cells, which was eectively delayed in C6/Bcl-2 cells (Figure 4a, b) . In agreement with observations in the etoposideinduced apoptosis, Bcl-2 overexpression signi®cantly prevented ceramide formation induced by TNF-a or cisplatin (Figure 4c,d ). Moreover, in order to verify whether such preventive eects of Bcl-2 are limited to C6 cells stably transfected with Bcl-2, Bcl-2 was transiently expressed in U87-MG human glioblastoma cells. As shown in Figure 5a , the Bcl-2 level reached the maximal level at 24 h after transfection with human bcl-2 gene. When Bcl-2 overexpressing cells (U87-MG.Bcl-2) and control cells transfected with empty vector (U87-MG.Vector) were exposed to 40 mM etoposide, 80% of U87-MG.Vector and 35% of U87-MG.Bcl-2 became apoptotic at 36 h (data not shown). In addition, ceramide production in U87-MG.Bcl-2 was much lower than that of U87-MG.Vector (Figure 5b ), indicating that transient expression of Bcl-2 also prevented etoposide-induced ceramide accumulation in U87-MG cells.
Bcl-xL is also shown to present the various apoptotic events , Decaudin et al., 1997 . Therefore, we next examined the inhibitory eect of Bcl-xL on ceramide generation in C6 cells transiently transfected with Bcl-xL. As shown in Figure  6a , the Bcl-xL level reached the maximal level at 24 h after transfection with human bcl-xL gene. When BclxL overexpressing cells (C6.Bcl-xL) and control cells transfected with empty vector (C6.Vector) were exposed to 40 mM etoposide, apoptotic cell death in C6.Bcl-xL decreased to almost 10% of control cells at 24 h (data not shown) and ceramide production in C6.Bcl-xL was much lower than that of C6.Vector (Figure 6b ), indicating that transient expression of BclxL also prevented etoposide-induced ceramide accumulation.
In order to further assess the inhibitory eect of Bcl-2 on ceramide generation and to verify how much overexpression of Bcl-2 is actually required to prevent ceramide generation, we classi®ed a total of nine independent clones into three groups depending on the levels of Bcl-2 protein; low level (C6/Bcl-2 L), medium level (C6/Bcl-2 M) and high level (C6/Bcl-2 H), as shown in Figure 
Effect of Bax overexpression on ceramide formation and SMase activation
Since we found that Bax facilitated etoposide-induced apoptosis (Figure 2 ), it is of great interest to determine whether etoposide-induced ceramide formation is aected by Bax. As shown in Figure 3a Figure 3c ). These results demonstrate that the ceramide response to etoposide was independent of Bax.
Since Bcl-2 and Bcl-xL levels in C6/Bax cells were signi®cantly higher than those in C6/Neo cells ( Effects of Bax or Bcl-2 overexpression on release of mitochondrial cytochrome c and activation of caspases-9 and -3 induced by etoposide Cytochrome c is released into the cytosol following induction of apoptosis by many dierent stimuli (Liu et al., 1996; Kluck et al., 1997; Reed, 1997; Green and Reed, 1998) . Therefore, the eects of etoposide treatment on release of mitochondrial cytochrome c and the resultant activation of caspases-9 and -3 were compared in C6/Neo, C6/Bcl-2, and C6/Bax cells. The release of cytochrome c into the cytosol occurred at 3 h, 12 h, and 1.5 h after the etoposide treatment in C6/Neo, C6/Bcl-2, and C6/Bax cells, respectively (Figure 10a ). In agreement with previous reports (Kluck et al., 1997; Yang et al., 1997; Jurgensmeier et al., 1998; Shimizu et al., 1999) , our results indicated that the cytochrome c releasing activity can be modulated by Bcl-2 and/or Bax. The detectable processing of caspase-9 was evident at 6 h after etoposide treatment in C6/Neo cells, but occurred at 12 h in C6/Bcl-2 cells (Figure 10b ). However, in C6/ Bax cells, caspase-9 was rapidly processed to the active fragment (Figure 10b ). The processing of immunoreactive 32-kDa procaspase-3 (CPP32) occurred as early as 6 h after the etoposide treatment in C6/Neo cells, but was delayed in C6/Bcl-2 cells (Figure 10c ). On the other hand, overexpression of Bax promoted the degradation of the levels of CPP32. These immunoblot results were well correlated with the changes in caspase-3 activity measured spectrophotometrically in these three types of cells (Figure 10d ).
Discussion
We have previously shown that cell permeable ceramide analog, C 2 -ceramide, induced apoptosis in C6 glioma cells (Yoshimura et al., 1997) . More recently, we have also observed that inhibition of the etoposide-induced ceramide formation by inhibitors of SMase prevented apoptotic cell death. In contrast, enhancement of ceramide accumulation through inhibition of its metabolism with an inhibitor of glucosylceramide transferase potentiated the etoposide-induced apoptosis (Sawada et al., in press ). These results suggest that ceramide acts as a potential mediator of apoptosis in C6 glioma cells.
Bcl-2 has been shown to protect a variety of cell types from apoptosis induced by an array of chemotherapeutic agents (Hickman, 1992; Reed, 1997; Tsujimoto, 1998) . In the present study, we have observed that etoposide-induced apoptosis was also prevented in C6 glioma cells overexpressing Bcl-2. However, it should be noted that this preventive eect of Bcl-2 was only transient and that overexpression of Bcl-2 did not completely prevent, but delayed the progression of apoptosis induced by etoposide, TNF-a, and cisplatin. Such eect to delay cell death has also been seen in other cell types overexpressing Bcl-2 (Yin and Schimke, 1995) , or in other anti-apoptotic members such as Mcl-1 (Reynolds et al., 1994) and A1 . As far as we know, there were no previous reports demonstrating that Bcl-2 overexpression could completely block apoptotic cell death. Therefore, the overexpression of Bcl-2 or homologues may confer a survival advantage to the cells rather than a de®nitive protection. The mechanism of action of Bcl-2 has remained elusive up to now. It has been suggested that Bcl-2 inhibits the release of mitochondrial cytochrome c leading to caspase-3 activation, thereby resulting in protection of apoptosis (Smyth et al., 1996; Kluck et al., 1997; Yang et al., 1997; Green and Reed, 1998) , or that it inhibits apoptosis by suppressing the formation of reactive oxygen species (ROS) (Hockenberry et al., 1993) . However, there is an opposing proposal that Bcl-2 can protect cells from death independently of ROS, since cell death can be rescued by Bcl-2 eectively even in the absence of ROS (Shimizu et al., 1995) . More recently, it has been shown that Bcl-2 and Bcl-xL prevent both permeability transition and cytochrome c release induced by Bax in isolated murine mitochondria (Narita et al., 1998; Simizu et al., 1999) . It remains unclear whether Bcl-2 is associated with ROS production.
On the other hand, Bcl-2 may interfere with the initiation of the ceramide signaling pathway, since it exerts an inhibitory eect on ceramide formation in two previous reports (Yoshimura et al., 1998; Tepper et al., 1999) . In contrast, some recent studies have shown that Bcl-2 overexpression did not aect ceramide accumulation in response to certain anti-cancer drugs Allouche et al., 1997) or receptor agonists (Dbaibo et al., 1997 , Wiesner et al., 1997 . However, in these individual studies, only a single overexpressing clone was used and there is no precise assessment regarding the expression levels of Bcl-2 or Bcl-xL. Therefore, these discrepancies may be explained by dierences in the extent of Bcl-2 expression, cell death inducer, and cell type. In the present study, we assessed the inhibitory eect of Bcl-2 on ceramide formation using distinct apoptotic stimuli such as etoposide, cisplatin, and TNF-a and also in dierent cell types (C6 and U87-MG cells). The results obtained here indicate that inhibition of ceramide formation may require a high level of Bcl-2 expression, almost 10-fold more than the control level, and that its low expression may not inhibit ceramide formation but can prevent apoptotic cell death, through blockade of the further downstream eector(s). Interestingly, it has been previously reported that Bcl-2 inhibits apoptotic process in a dose-dependent manner (Shimizu et al., 1996) . Therefore, the dierences among investigators in the eect of Bcl-2 on the ceramide pathway could be explained by the levels of Bcl-2 expression.
We have observed that intracellular ceramide regulates Bax/Bcl-2 expression upstream of caspases during etoposide-induced apoptosis in C6 glioma cells (Sawada et al., in press ). Taking into account this and the present observations that the overexpression of Bcl-2 inhibits ceramide formation, it is likely that Bcl-2 acts at both upstream and downstream of ceramide. The ceramide formation by etoposide resulted in a timedependent increase, since the etoposide-induced ceramide accumulation downregulates the level of Bcl-2, which prevents the activation of neutral SMase. bcl-x, ®rst identi®ed by Boise et al. (1993) , is a gene with signi®cant overall sequence and structural homology with bcl-2. By alternate splicing, bcl-x encodes two important protein isoforms; the longer isoform, Bcl-xL, inhibits apoptosis whereas the shorter isoform, Bcl-xs, promotes apoptosis by acting as a dominant inhibitor of Bcl-2 and Bcl-xL (Boise et al., 1993 . Several previous reports have demonstrated that there are many similarities between Bcl-2 and Bcl-xL in anti-apoptotic functions such as cytochrome c release and caspase activation (Decaudin et al., 1997 . In the present study, transient Bcl-xL overexpression also exerted inhibitory eects on ceramide accumulation and apoptotic cell death in response to etoposide. Taken together, Bcl-xL also appears to prevent the activation of neutral SMase in the ceramide-mediated apoptotic pathway.
In contrast, Bax had no eects on ceramide formation during the etoposide-induced apoptosis in the stable C6 transfectants with bax gene. However, to rule out the eect of overexpressed levels of Bcl-2 and Bcl-xL in the stable C6/Bax transfectants on ceramide formation, transient expression with bax gene was further performed. In these transient transfectants, increased expression of Bcl-2 and Bcl-xL was not observed. Although etoposide-induced apoptosis was accelerated, ceramide formation was almost equal to that of vector-transfected cells. Moreover, similar results were also obtained when U87-MG cells transiently transfected with Bax were exposed to etoposide. Therefore, the lack of ceramide response by Bax overexpression was considered not to be due to the transfection mode (stable or transient) or the cell type. Based on our results, Bax promotes apoptotic cell death via targeting mitochondria and inducing cytochrome c release at downstream of ceramide formation in the etoposide-induced apoptosis. Recent reports supporting this notion have shown that Bax can directly induce cytochrome c release from mitochondria without requirement for caspases (Jurgensmeier et al., 1998; Rosse et al., 1998; Pastorino et al., 1998) . More recently, Bax and Bad were shown to directly interact with and to accelerate the opening of mitochondrial voltage-dependent anion channel (also called porin channel), through which cytochrome c is released (Simizu et al., 1999) .
Since Bad has been shown to accelerate apoptosis as one of pro-apoptotic proteins Zha et al., 1996) and dephosphorylation of Bad at the site of serine 136 has been recently implicated as a target for ceramide signaling of apoptosis (Basu et al., 1998) , we examined changes in the levels of Bad by immunoblot analysis. However, the expression of Bad protein was almost constant during the apoptotic process (data not shown). Although our study does not address the eect of Bad overexpression on ceramide generation, it is unlikely that Bad overexpression could aect ceramide generation. Bad may function at downstream of ceramide, since ceramide aects the phosphorylation state of Bad protein (Basu et al., 1998) . In addition, Bad as well as Bax is shown to directly induce cytochrome c release from mitochondria through the opening of mitochondrial voltagedependent anion channel (Simizu et al., 1999) . These results suggest that Bad overexpression might not have any eects on ceramide formation similar to Bax overexpression. However, further investigations will be required to draw a de®nite conclusion. Figure 10 Release of mitochondrial cytochrome c, processing of caspase-9 and caspase-3 during etoposide-induced apoptosis in C6/Neo, C6/Bcl-2, and C6/Bax cells. (a,b,c) C6/Neo, C6/Bcl-2, and C6/Bax cells were harvested after exposure to 40 mM etoposide for indicated periods. Release of cytochrome c from mitochondria to cytosol (a), and processing of caspases-9 (b) and -3 (c) were analysed by Western blotting with each speci®c antibody as described in Materials and methods. Results are representative of two separate experiments with compatible outcomes. (d) The cellular extracts (40 mg of protein) were incubated with 50 mM Ac-DEVD-MCA, a substrate for caspase-3 at 378C for 1 h. Levels of released 7-amino-4-methylcoumarin were measured using a spectro¯uorometer as described in Materials and methods. Data are means+s.d. from three independent experiments, each performed in triplicate It has been reported that in Jurkat cells and cerebellar granule cells, Bax-induced cell death activates not only the caspase-dependent but also independent pathways (Xiang et al., 1996 , Miller et al., 1997 . The caspase-independent pathway may be required for actual cell death, since caspase inhibitors prevented DNA fragmentation, but failed to block Bax-induced cell death. Therefore, it was suggested that in several types of cells, Bax induces the caspaseindependent pathway accompanied with necrosis-like morphological changes such as cytosolic vacuolation. In the present study, however, Bax-induced cell death displayed the hallmark features of apoptosis such as nuclear condensation, cell shrinkage, and DNA fragmentation, all of which were blocked by z-VAD.FMK. Moreover, this caspase inhibitor could block delayed cell death seen in Bcl-2 overexpressed cells. These ®ndings indicate that a large fraction of the etoposide-or Bax-induced death pathway in glioma cells should be caspase-dependent.
Previous studies have reported that Bax promotes etoposide-or cisplatin-induced cell death in the murine IL-3-dependent cell line FL5.12 (Simonian et al., 1996) , mouse embryonic ®broblasts derived from p53 and bax knockout mice (McCurrach et al., 1997) , and human breast cancer MCF-7 cells (Sakakura et al., 1997) . We also demonstrated that Bax overexpression enhanced the sensitivity to etoposide of C6 or U87-MG glioma cells. On the contrary, other studies reported that Bax fails to sensitize cells to the etoposide-induced apoptosis. Bax overexpression sensitized human ovarian tumor cells to paclitaxel, vincristine and doxorubicin, but not to carboplatin, etoposide and hydroxyurea (Strobel et al., 1996) . Bax overexpression enhanced the sensitivity of human erythroleukemia cells to ara-C, doxorubicin and SN-38, but had no eect on the dose response to etoposide (Kobayashi et al., 1998) . However, in these reports, cell lines expressing mutant or null type p53 were used. These p53 status are in contrast to those in the present study in which etoposide induced accumulation of wild-type p53 (data not shown), indicating that the ability of Bax overexpression to sensitize cells to DNAdamaging agents would depend on p53 status of the cell lines used. This hypothesis supported by the observation that Bax overexpression in thymocytes from transgenic mice enhances radiation-induced apoptosis only when the intact p53 pathway is operative (Brady et al., 1996) . In summary, we have shown the inhibitory eects of Bcl-2 family on the ceramide-mediated apoptotic pathway in glioma cells. Bcl-2 is considered to act not only downstream of ceramide to inhibit cytochrome c release followed by caspase activation, but also upstream of or at SMase to prevent ceramide generation. In contrast, Bax may act downstream or independent of ceramide to directly activate the release of cytochrome c. Further investigations regarding the ceramide pathway, especially identi®ca-tion of the upstream and downstream components of the SM-ceramide signaling pathway, will lead to better understanding of the molecular mechanism of apoptosis induced by chemotherapeutic agents, and give us a novel approach for the treatment of malignant gliomas.
Materials and methods

Reagents
DMEM was purchased from Nipro (Osaka, Japan). Penicillin/streptomycin was from Gibco-BRL (Grand Island, NY, USA). FBS was from Irvine Scienti®c (Santa Ana, CA, USA). Hoechst 33258 (bisbenzimide) staining dye was from Wako (Osaka, Japan). Immobilon-P membranes were from Millipore (Bedford, MA, USA). The tetrapeptide substrates for caspase-3, Ac-DEVD-MCA, and a protease inhibitor E-64 were obtained from Peptide Institute (Osaka, Japan). Escherichia coli diacylglycerol kinase was from Sigma (St. Louis, MO, USA). [g-32 P]ATP and ECL Western blotting detection reagents were from Amersham (Buckinghamshire, UK). [3-14 C]Serine (49 mCi/mmol) was from ICN Pharmaceuticals (Irvine, CA, USA). High performance thin-layer chromatography (HPTLC) plates were from Merck (Darmstadt, Germany). The broad spectrum caspase inhibitor, z-VAD.FMK was from Enzyme Systems Products (Dubin, CA, USA). Plasmid constructs pUC-CAGGS, pUC-CAGGS.Bcl-2, pUC-CAGGS.Bcl-xL, and pUC-CAGGS.Bax were generously provided by Dr Y Tsujimoto (Osaka University Graduate School of Medicine). Trans-It was purchased from Takara (Tokyo, Japan). Etoposide was supplied from Nippon-Kayaku (Tokyo, Japan). Cisplatin was from Bristol-Meyers Squibb (Tokyo, Japan). TNF-a was purchased from R&D Systems (Minneapolis, MN, USA). The primary antibodies used were anti-rat-Bcl-2 monoclonal antibody, anti-mouse Bax polyclonal antibody, anti-rat Bad monoclonal antibody, anti-rat Bcl-xL monoclonal antibody, antirat ICE (procaspase-1) monoclonal antibody, anti-rat CPP32 (procaspase-3) monoclonal antibody, anti-caspase-9 monoclonal antibody, anti-cytochrome c polyclonal antibody (Santa Cruz Biotechnology; Santa Cruz, CA, USA), and anti-mouse actin monoclonal antibody (Calbiochem-Novabiochem International; Cambridge, MA, USA). BCA protein assay reagents were obtained from Pierce (Rockford, IL, USA). Other chemicals were of the highest quality available.
Cells
C6 cells and U87-MG cells were obtained from Human Science Research Resource Bank (Osaka, Japan). The cells were maintained in DMEM supplemented with 10% (v/v) FBS, 100 units/ml penicillin and 100 mg/ml streptomycin (FBS/DMEM) in a humidi®ed atmosphere containing 5% CO 2 at 378C. For treatment with etoposide, cisplatin, and TNF-a, the optimal concentration of each agent was determined from the dose-response curve versus the extent of cell death (data not shown), as previously reported (Yoshimura et al., 1997; Sawada et al., 2000) .
Stable transfection of Bcl-2 and Bax in C6 cells
C6 cells were stably transfected with pUC-CAGGS.Bcl-2 using trans-It. For stable transfection of human bcl-2 cDNA, 2 mg of human bcl-2 cDNA was added to 8 ml of trans-It, followed by addition of 100 ml of serum-free RPMI 1640 medium and then the resultant mixture was incubated for 10 min at room temperature. The adherent cells were washed twice with serum-free RPMI 1640 medium, followed by addition of the DNA mixture to the culture dish. After incubation for 4 h (5% CO 2 , 378C), the medium was replaced with FBS/DMEM. After an additional incubation for 24 h, medium was replaced by 10% FBS/DMEM containing 800 mg of G418 per ml and incubated for up to 2 weeks. Neomycin-resistant cells were identi®ed and cloned by limiting dilution. C6 cells transfected with the murine bax gene and the neomycin resistant control gene were kindly provided by Dr KM Rich (Washington University, St. Louis, MO, USA).
Transient transfection of Bcl-2, Bcl-xL, and Bax in C6 and U87MG cells C6 and U87MG cells were plated at 1610 4 on 60-mm dish on day 0. On day 2, medium was changed to serum-free RPMI 1640 medium, and cells were transfected with 2 mg of human bcl-2 cDNA, human bcl-xL cDNA, or mouse bax cDNA for 4 h using trans-It. After transfection medium was changed to FBS/DMEM, cells were cultured for indicated periods of time.
Fluorescent microscopy
Apoptotic cells stained with Hoechst 33258 were quanti®ed by¯uorescent microscopic analysis (Yoshimura et al., 1998) . Brie¯y, cells treated with apoptotic inducers were harvested and ®xed in 1% glutaraldehyde for 30 min. The cells were rinsed with PBS and stained with 10 mM Hoechst 33258 for 10 min. Nuclear morphology was observed under a¯uor-escent microscope (Olympus BX60, Tokyo, Japan).
SMase Assay
Membrane and cytosolic fractions were prepared from cells after exposure to apoptotic agents. Brie¯y, cells were washed in ice-cold PBS and homogenized in lysis buer (25 mM Tris/ HCl, pH 7.5, 2 mM EDTA, 2 mM EGTA, 1 mM phenylmethylsulfonyl¯uoride, and 20 mg/ml E-64) with 20 strokes in a glass homogenizer with a Te¯on pestle (Iuchiseieido, Tokyo, Japan). The post-nuclear homogenate was centrifuged at 100 000 g for 1 h and the pellet was resuspended in lysis buer. The activities of both neutral and acid SMases were determined using a mixed micelle assay system as described (Okazaki et al., 1990; Wiesner et al., 1997) . For measuring neutral SMase activity, the membrane fractions (20 mg protein) were mixed with [methyl-14 C]SM (40 000 c.p.m. in 1 nmol of bovine brain SM in 0.25% Triton X-100 solubilized by sonication) in 0.1 M Tris/HCl buer (pH 7.4) containing 6 mM MgCl 2 . After incubation for 30 min at 378C, the reaction was stopped by the addition of 1.5 ml of chloroform: methanol (2 : 1, v/v) followed by 0.2 ml of H 2 O. After phase separation, a portion of the upper phase was transferred to scintillation vials and the radioactivity was determined by liquid scintillation counting. Negative controls containing no enzyme was run concomitantly. Acid SMase activity in membrane was measured as above except that the Tris/HCl buer was replaced with 0.1 M sodium acetate buer (pH 5.5) containing 5 mM EDTA.
Measurement of cellular ceramide level by diacylglycerol kinase assay
Cellular ceramide level was measured as previously described (Yoshimura et al., 1998) . Brie¯y, lipids extracted from cells were ®rst treated in 0.1 M KOH in chloroform:methanol (1 : 2, v/v) at 378C for 1 h. Ceramide was converted to ceramide 1-[ 32 Assay for activity of caspase proteases Cells were harvested after exposure to etoposide for indicated periods of time and washed three times with PBS, and then suspended in buer containing 50 mM Tris/HCl (pH 7.4), 1 mM EDTA and 10 mM EGTA. After addition of 10 mM digitonin, cells were incubated at 378C for 10 min. Complete cell lysis was veri®ed by the amount of released LDH activity. Lysates were centrifuged at 900 g for 3 min, and the resulting supernatant (40 mg protein) was incubated with 50 mM of enzyme substrate at 378C for 1 h. Levels of released 7-amino-4-methylcoumarin (AMC) were measured using spectro¯uorometers (Hitachi F-3000 and F-2000, Japan) with excitation at 380 nm and emission at 460 nm (Yoshimura et al., 1998) . Excitation and emission slit widths were adjusted to 10 and 20 mm, respectively. One unit was de®ned as the amount of enzyme required to release 0.22 nmol AMC per min at 378C.
Preparation of cytosolic fraction for measurement of cytochrome c release
Cytosolic extracts were prepared according to the previous report . Brie¯y, cells were collected at the indicated times and washed twice with ice-cold PBS and resuspended in 100 ml of extraction buer (50 mM Hepes-KOH, pH 7.4, 220 mM mannitol, 68 mM sucrose, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM dithiothreitol, 1 mM phenylmetylsulfonyl¯uoride, and 1 mM E-64). After incubation on ice for 20 min, cells were homogenized with 20 strokes in a glass homogenizer with a Te¯on pestle. Nuclei were removed by centrifugation at 1000 g for 10 min at 48C in a microcentrifuge. Supernatants were then further centrifuged at 10 000 g for 15 min at 48C. The supernatant was further clari®ed by centrifugation at 100 000 g for 60 min at 48C.
Western blot analysis
For the analysis of processing of procaspases, cells were solubilized with ice-cold lysis buer containing 1% Triton X-100, 50 mM NaCl, 25 mM HEPES (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 mM phenylmetylsulfonyl¯uoride, and 10 mg/ ml E-64. Insoluble materials were removed by centrifugation at 10 000 g for 10 min. Extracted proteins (60 mg/ well) were separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS ± PAGE) on 13% polyacrylamide gels, and were electrophoretically transferred onto Immobilon-P membrane. Blocking was performed in Tris-buered saline containing 5% skimmed-milk powder and 0.1% Tween-20. The membranes were probed with antibodies against CPP32 (procaspase-3), ICE (procaspase-1), caspase-9, cytochrome c, Bcl-2, Bax, Bcl-xL, Bad or actin. Detection was performed with ECL system. Protein content was determined with BCA protein assay using bovine serum albumin as a standard.
Statistical analysis
Data are expressed as means+s.d. Signi®cance was assessed by two-way ANOVA, followed by Schee's post-hoc test. P values less than 0.01 was considered as signi®cant.
Abbreviations TNF, tumor necrosis factor; SM, sphingomyelin; SMase, sphingomyelinase; ROS, reactive oxygen species; FBS, fetal bovine serum; DMEM, Dulbecco's modi®ed Eagle's medium; HPTLC, high performance thin-layer chromatography; PBS, phosphate-buered saline; DMSO, dimethyl sulfoxide; AMC, 7-amino-4-methylcoumarin; SDS ± PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis.
